Polo-like kinase 4 (PLK4) as a therapeutic target in breast cancer
Carcinogenesis · 2025
DOI: 10.1093/carcin/bgaf067 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Carcinogenesis, 2025. Verfasst von Armen Parsyan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy and Cell Biology, Schulich School of Medicine & Dentistry, Western University, London, ON N6A 5C1, Canada. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Breast Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Breast Cancer Canada, Academic Health Sciences Centre, Academic Medical Organization of Southwestern Ontario.
Abstract (Originalsprache)
Polo-like kinase 4 (PLK4) is a key kinase regulating centriole duplication, centrosome maturation, cytokinesis and other cellular processes. Growing evidence suggests a critical role of PLK4 in the development and progression of various cancers. In many cancer types, its upregulation leads to pro-oncogenic phenotypes, while its pharmacologic inhibition leads to anticancer effects. Functionally, PLK4 affects cancer cell proliferation, growth, motility, invasion, migration, epithelial-mesenchymal transition, apoptosis and other critical oncogenic processes. In breast cancer, PLK4 is associated with centrosome amplification, aneuploidy and chromosomal instability, promoting invasive phenotypes and resistance to cancer cell death. PLK4 shows great promise as a prognostic and predictive biomarker in breast cancer. It is commonly found to be overexpressed in primary human breast cancers and is associated with poor oncologic outcomes, clinicopathologic parameters, and high-risk subtypes. Various compounds, such as CFI-400945, centrinone B, and others have been developed to inhibit PLK4 activity. Preclinical studies have shown that PLK4 inhibitors lead to decreased proliferation, growth and migration and increased breast cancer cell death. Moreover, PLK4 inhibition can serve to enhance the effects of other treatments, including radiotherapy. Clinical studies have been initiated with some of these compounds in cancer patients, including those with breast cancer. This manuscript discusses the role of PLK4 as a promising therapeutic target in breast cancer, one of the most common causes of morbidity and mortality in women.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anatomy and Cell Biology, Schulich School of Medicine & Dentistry, Western University, London, ON N6A 5C1, Canada.
- Verspeeten Family Cancer Centre, London Health Sciences Centre and London Health Sciences Centre Research Institute, London, ON N6A 5W9, Canada.
- Department of Oncology, Schulich School of Medicine & Dentistry, Western University, London, ON N6A 5W9, Canada.
- Department of Surgery, Schulich School of Medicine & Dentistry, London, ON N6A 4V2, Canada.
- St Joseph's Health Care, London, ON N6A 4V2, Canada.
ORCID-Profile: Armen Parsyan, Harjot Athwal, Vasudeva Bhat, Alison L Allan
Förderung
- Breast Cancer Canada
- Academic Health Sciences Centre
- Academic Medical Organization of Southwestern Ontario
- London Regional Cancer Program Catalyst Grant
- Western University
- Cancer Research Society
- CIHR
- Institute of Cancer Research
Zitieren
APA
Parsyan, A., Athwal, H., Bhat, V., & Allan, A. L. (2025). Polo-like kinase 4 (PLK4) as a therapeutic target in breast cancer. Carcinogenesis. https://doi.org/10.1093/carcin/bgaf067
Vancouver
Parsyan A, Athwal H, Bhat V, Allan AL. Polo-like kinase 4 (PLK4) as a therapeutic target in breast cancer. Carcinogenesis. 2025. doi:10.1093/carcin/bgaf067
BibTeX
@article{Parsyan2025,
author = {Parsyan, Armen and Athwal, Harjot and Bhat, Vasudeva and Allan, Alison L},
title = {Polo-like kinase 4 (PLK4) as a therapeutic target in breast cancer},
journal = {Carcinogenesis},
year = {2025},
doi = {10.1093/carcin/bgaf067}
}
EUVIMED